StemCell Therapy

DELMAR, N.Y. (NEWS10) The LymeSeq test could change the way you are tested for Lyme disease. They will be taking peoples blood later this month and they already have 80 participants.

The samples will be collected and brought to SUNY Adirondack Community College.

Tiny ticks, some as small as a poppy seed, can cause serious illness to those they attach to. Your blood is their food and now the Stram Center of Integrative Medicine, in part with Adirondack CC, wants to test your blood to find out if tick born diseases like Lyme disease can be detected in your DNA.

The new test is called LymeSeq.

People that might have had Lyme, tested positive, or have been treated for Lyme in the past and that just dont feel well or that feel that they may have Lyme disease, thats kind of what were looking for, Jennifer Mager NP, of the Stram Center, said.

If that applies to you, you might want to sign up for the clinical study.

Mager says the Western Blot Test currently used is deeply flawed.

Probably detects less than 50 percent of cases of Lyme disease.

The LymeSeq test will also detect other infections carried by ticks.

It also can detect some of the big co-infections that were seeing and that can be just as if not more problematic than Lyme.

In Virginia, doctors must tell patients that get a negative Western Blot result that that doesnt mean they dont have Lyme disease.

We see so many sick people with Lyme disease and a lot of people never have ever had a positive test but have multiple known tick bites in their history.

New York State Health Department Research Scientist Bryon Backenson says he believes errors are made in regards to when patients receive the test.

I think often we get a lot of negatives because the test is done a little bit too early, but again, it is sort of what we have so far, and if theres a better way to test for Lyme disease that gives good consistent results, wed be all for it, Backenson said.

Information from the CDC.

The clinical study is being held on July 27 at the Stram Center in Delmar.

Call 518-689-2244 ext.*108 to arrange an appointment. Appointments are preferred, but a limited number of walk-ins will be accommodated as time allows.

For inquiries, please contact the Stram Center atlymelab@stramcenter.com.

Learn more about ticks and tick prevention from the Centers for Disease Control and Prevention.

Like Loading...

Visit link:
Clinical trial being held for Lyme disease test - wwlp.com

In a new set of rules, the Vatican outlawed gluten-free bread for Holy Communion. Sean Dowling (@seandowlingtv) has more. Buzz60

Pope Francis during the communion at the Easter Vigil mass in Saint Peter's Basilica at the Vatican in April.(Photo: Claudio Peri, EPA)

The expanding market for wine and bread used as part of Catholic masses prompted Pope Francis to remind priests and bishops across the world that gluten-free bread is a no-go when it comes to communion.

The pope issued a letter in mid-June saying all bread used during communion must have at least some gluten, anaturally occurring protein in wheat, whichis common in breads, pastas, cakes and cereals.

"Hosts that are completely gluten-free are invalid matter for the celebration of the Eucharist," wrote Cardinal Robert Sarah on behalf of the pope. Low-gluten hosts,he added, can be used, "provided they contain a sufficient amount of gluten to obtain the confection of bread without the addition of foreign materials and without the use of procedures that would alter the nature of bread."

Church rules dictate bread used for communion must be recently made, be unleavened and made purely of wheat. Any other additions including fruit, sugar or honey make the bread unusable.

The directive was a reiteration of a 2003 missive from the church about thelegitimacy of holy wine and bread. At Catholic masses, congregants eat bread and drink wine, which signify the body and blood of Jesus Christ.

When and where someone was born could be an indicator to if they have celiac disease. Keleigh Nealon (@keleighnealon) has the story. Buzz60

Apart from the gluten rules, the churchallows for bread and wine made with genetically modified organisms and mustum, a type of grape juice.

Sarah said he issued the letter to help churches validate the bread and wine they're using.

"Until recently it was certain religious communities who took care of baking the bread and making the wine for the celebration of the Eucharist," the letter said. "Today, however, these materials are also sold in supermarkets and other stores and even over the Internet."

Read more:

The church's stance comes as more people adopt a gluten-free diet and itspromised health benefits.

A national study in 2016found about 2.7 million Americans avoid gluten, although just 1.8 million had celiac disease. People with celiac disease can endure damage to their small intestines if they eat gluten, according to the National Institutes of Health.

Yet the merits of a gluten-free diet have been challenged by researchers, some of which have chalked it up to a passing fad. Lynn Wagner, an integrative medicine specialist at BayCare Clinic in Wisconson, said people who choose gluten-free foods think they're beinghealthy, while reality suggests gluten-free foods offer little to no nutritious value.

Follow Sean Rossman on Twitter: @SeanRossman

Read or Share this story: https://usat.ly/2uNbN9w

See the original post:
Pope Francis said gluten-free bread is a no-go when it comes to communion - USA TODAY

The ongoing story of Charlie Gard - a baby born in London with a rare genetic disorder known as Mitochondrial Depletion Syndrome - has gained international attention, with such prominent figures as Pope Francis and President Donald Trump commenting on his familys ordeal.

Charlie, born on August 4, 2016, has been on life support for several months at the Great Ormond Street Hospital in London. As his condition continues to deteriorate, his parents are battling with the European courts over how to move forward with his care.

Last week, New York Presbyterian/Columbia Medical University Hospital offered to administer experimental treatment therapy to Gard as long as the British government approves a safe medical transfer to the United States. Thus far, the courts have denied the transfer, but Charlies parents have continued their battle with the legal system.

Meanwhile, Charlies incredibly rare form of mitochondrial disease has generated global attention. Here are some of the common questions about Mitochondrial Depletion syndrome.

MDS is one of a suite of rare disorders that affect the mitochondria - often described as the tiny powerhouses of the cell. Certain genes ensure that these mitochondria are healthy and produce the energy the cells need. Genes come in pairs, one copy comes from the mother and one from the father. When a baby has MDS, it means that both copies received from the parents for this particular gene - the one that keeps mitochondria healthy - are defective. The result is progressive muscle weakness and devastating multi-organ damage.

This disease is very uncommon, with perhaps fewer than 100 cases in the range of related disorders reported worldwide, according to a 2014 study.

Initially, development may appear normal; however, before these children reach 24 months of age, they usually start exhibiting certain signs of muscle weakness -- for example, weakening of eye muscles leading to droopy eyelids and facial weakness. These children may also exhibit signs of organ failure, such as brain and nervous system problems leading to seizure activity, hearing loss, liver damage and difficulty walking, talking, and swallowing.

The prognosis, unfortunately, is very poor. Many children with this condition begin having lung muscle weakness early in life. Normally, this progresses rapidly to respiratory failure and death within a few years of onset. The most common cause of death is infection of the lungs.

Although supportive therapy is available to help treat the conditions that accompany this syndrome - such as the seizures and hearing loss - there is currently no cure for MDS. Experimental therapies tested on mice are intended to target specific defective areas of the mitochondria. Thus far, these treatments have shown only modest success in these animals and some have begun to be tested in a few children. The parents of an American child with a different type of mitochondrial disorder spoke to Gard's parents, according to the Associated Press, about a nucleoside therapy treatment they have been using for their now 6-year-old son who appears to have shown some modest improvement.

Devika Umashanker, M.D., is a recent graduate of the Obesity Medicine fellowship at Weill-Cornell Medical College.

See the original post:
Baby Charlie Gard's medical condition: What you need to know - ABC News

Dive Brief:

After a disappointing initial public offering and a tough debt load looming for 2018 and 2019, Kadmon spent the latter half of 2016 putting its house in order, with a credit agreement renegotiation, staff cuts and optimization of its sales strategies. While these changes work in the background, in the foreground the company spent its R&D day yesterday celebrating some good news for KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, which has shown similar efficacy to other drugs in development such as Imbruvica (ibrutinib) and Jakafi (ruxolitinib).

"These positive interim findings indicate activity and a favorable safety profile of KD025 in cGVHD, a fatal disease with no approved therapies,"said John Ryan,CMO of Kadmon. Steroids are the current standard therapy for cGVHD and have severe side effects associated with long-term use. We are pleased to see that the majority of patients in the first cohort have been able to reduce their steroid doses, indicating that KD025 potentially offers a well-tolerated treatment option for cGVHD patients."

The company will roll out further data for the other two cohorts, with more results on twice-daily dosing at 200 mg, and data on once daily dosing at 400 mg, during 2018. According to Jefferies analysts, Kadmon will seek breakthrough designation for KD025 by the end of 2017, and begin a clinical trial in newly diagnosed cGVHD in early 2018.

KD025 is also being assessed in a placebo-controlled Phase 2 clinical trial in moderate to severe psoriasis, and an open-label Phase 2 clinical trial in idiopathic pulmonary fibrosis. The company's pipelineincludes tesevatinib, in Phase 2 for non-small cell lung cancer and glioblastoma, and in Phase 2 and 3 for polycystic kidney disease.

Chronic graft-versus-host disease (cGVHD) is a complication of allogeneic bone marrow transplantation and hematopoietic stem cell transplantation, often used to treat myeloma and leukemia. Symptoms affect skin, mouth, liver, eyes, gastrointestinal tract, vagina, esophagus, musculoskeletal tissue and lungs. While the global GVHD market is still a relatively small one, worth around $360 million in 2016, rising to an estimated $640 million by 2026, according to Visiongain.cGVHD affects up to 50% of patients who survive longer than three months post-transplant and has a major impact on quality of life in otherwise successfully treated patients.

More:
Kadmon ROCKing some positive results - BioPharma Dive

In a step toward one of stem cell sciences chief goals, UW-Madison researchers have grown functional human artery cells that helped lab mice survive heart attacks.

The development, from the lab of stem cell pioneer James Thomson, could help scientists create arteries to use in bypass surgeries for cardiovascular disease, the nations top killer. Several challenges remain, however, and studies in people are years away.

This work provides valuable proof that we can eventually get a reliable source for functional arterial endothelial cells and make arteries that perform and behave like the real thing, Thomson said in a statement.

The research, reported Monday in the journal Proceedings of the National Academy of Sciences, is part of a federally funded effort at UW-Madison to create artery banks for cardiovascular surgery from universally compatible donors.

In a related project, other UW-Madison researchers are testing three-dimensional heart patches of heart muscle cells, grown from stem cells, in pigs. The goal is to replace diseased or damaged heart tissue in humans.

Since Thomson became the first scientist to successfully grow human embryonic stem cells in a lab in 1998, researchers around the world have been coaxing the universal cells into various cell types heart, pancreas, kidney, brain to develop therapies and better understand diseases.

Today, many researchers use cells reprogrammed to their embryonic state from mature cells known as induced pluri- potent stem, or iPS, cells as the raw material. Thomson helped discover iPS cells in 2007.

Many labs can convert embryonic stem cells or iPS cells into specific cell types, but developing specialized cell lines that are pure, functional and robust has been a challenge.

Thomson and his team set out to find a recipe for growing artery cells that would really function like arteries.

The researchers used two new techniques: single-cell RNA sequencing to identify genes highly expressed in cells that initiate artery development, and CRISPR-Cas9 gene editing to evaluate the function of the genes.

They found that five small molecules and growth factors are needed to encourage iPS cells to become functional artery cells. To their surprise, they discovered that insulin, a common growth factor that had been used before in trying to grow artery cells, actually inhibits such growth.

They used their recipe to make artery cells, and tested the cells in mice that had their left coronary arteries tied off to mimic heart attacks. Four weeks later, 83 percent of mice treated with the cells were alive, compared to 33 percent of mice that didnt get the cells.

We can use those cells to further create tissue-engineered arteries for bypass surgeries, said Jue Zhang, a scientist in Thomsons lab at the Morgridge Institute for Research and lead author of the study.

Developing off-the-shelf bypasses for surgery is the goal of an $8 million, seven-year grant UW-Madison received last year from the National Heart, Lung and Blood Institute to create universal artery banks.

The blood vessels of many cardiovascular disease patients arent suitable for use as bypasses, doctors say, and growing bypasses from individual patients stem cells would be timely and expensive. The hope is to use iPS cells from a rare population of genetically compatible donors to grow arteries anyone could use.

UW-Madison scientists, including engineers Tom Turng and Naomi Chesler and pathologist Igor Slukvin at the Wisconsin National Primate Research Center, plan to grow artery cells on scaffolds and test them in monkeys. If successful, the cells would be produced for human studies at the Waisman Biomanufacturing facility on campus.

The heart patches involve another $8.6 million, seven-year National Institutes of Health grant, shared with the University of Alabama-Birmingham and Duke University.

The patches involve three types of heart cells, derived from iPS cells, said Dr. Tim Kamp, a UW-Madison cardiologist and co-director of the universitys Stem Cell and Regenerative Medicine Center.

In studies in pigs, getting the patches to connect and survive when transplanted to pig hearts after heart attacks remains a challenge, Kamp said. Immune tolerance of the human grafts in pigs is another concern, he said.

But if such hurdles can be overcome, tests in humans could follow.

View original post here:
UW-Madison scientists grow functional artery cells from stem cells - Madison.com

Back to Browse Journals Journal of Hepatocellular Carcinoma Volume 4

Danijel Galun,1,2 Tatjana Srdic-Rajic,3 Aleksandar Bogdanovic,1 Zlatibor Loncar,2,4 Marinko Zuvela1,2

1Hepato-Pancreato-Biliary Unit, University Clinic for Digestive Surgery, Clinical Center of Serbia, 2Medical School, University of Belgrade, 3Institute for Oncology and Radiology of Serbia/Unit for Experimental Oncology, 4Emergency Center, Clinical Center of Serbia, Belgrade, Serbia

Abstract: Hepatocellular carcinoma (HCC) is characterized by a growing number of new cases diagnosed each year that is nearly equal to the number of deaths from this cancer. In a majority of the cases, HCC is associated with the underlying chronic liver disease, and it is diagnosed in advanced stage of disease when curative treatment options are not applicable. Sorafenib is a treatment of choice for patients with performance status 1 or 2 and/or macrovascular invasion or extrahepatic spread, and regorafenib is the only systemic treatment found to provide survival benefit in HCC patients progressing on sorafenib treatment. Other drugs tested in different trials failed to demonstrate any benefit. Disappointing results of numerous trials testing the efficacy of various drugs indicate that HCC has low sensitivity to chemotherapy that is in great part caused by multidrug resistance. Immunotherapy for HCC is a new challenging treatment option and involves immune checkpoint inhibitors/antibody-based therapy and peptide-based vaccines. Another challenging approach is microRNA-based therapy that involves two strategies. The first aims to inhibit oncogenic miRNAs by using miRNA antagonists and the second strategy is miRNA replacement, which involves the reintroduction of a tumor-suppressor miRNA mimetic to restore a loss of function.

Keywords: hepatocellular carcinoma, drug resistance, multimodal treatment, chemotherapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post:
Targeted therapy and personalized medicine in hepatocellular ... - Dove Medical Press

Margaretta Page, RN, MS, UCSF Neuro-Oncology Gordon Murray Caregiver Program, will discuss her experience in creating the first neuro-oncology caregiver program at UCSF and share some early caregiver survey data in a session entitled, "Improving Quality of Life for the Caregiver." Page's efforts to create the UCSF Neuro-Oncology Caregiver Program appear in a paper published in the June 2017 issue of Neuro-Oncology Practice.

"Neuro-oncology caregivers face unique challenges as they are caring for a loved one with a catastrophic, life-threatening diagnosis combined with progressive neurological decline that can produce great distress," Page said. "A tailored plan that includes information about the disease and disease transitions, the role of the caregiver, managing children in the home when a parent has a brain tumor, and the need for connection with others are among the high need areas."

Tobias Walbert, MD, PhD, MPH, Co-Director of the Hermelin Brain Tumor Center, Henry Ford Health System, is a board certified neurologist, neuro-oncologist and palliative care and hospice physician. His research focus includes helping patients and their families with symptom management, advance care planning, communication and end-of-life decision making.

Dr. Walbert, who believes that "cutting edge therapy needs to come together with a sense of family and a sense of hope," will share his approach to creating individualized supportive care plans for patients that begin with diagnosis and are evaluated and adapted to reflect evolving patient needs throughout the trajectory of the disease, in a breakout session entitled, "Supportive Care and Brain Tumors."

Break-out sessions are scheduled for Sat., Aug. 5. Additional topics include innovations in:

The ABTA National Patient & Family Conference, Redefining Survivorship Through Science, Technology and Clinical Innovation is being held at the Westin O'Hare in Rosemont, Ill., August 4-5. Advance registration is encouraged; walk-in registration will be based upon space availability.

To view the conference program and register, visit http://www.braintumorconference.org, or call 800-886-ABTA (2282) or email info@abta.org.

ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATIONFounded in 1973, the American Brain Tumor Association was the first national patient advocacy organization committed to funding brain tumor research and providing education and information for people of all tumor types and all ages. For more information, visit http://www.abta.org or call 800-886-ABTA (2282).

CONTACT: Jennifer Keljik, jkeljik@abta.org, 773-577-8790

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/personalized-medicine-extending-to-supportive-needs-of-brain-tumor-patientscaregivers-300484724.html

SOURCE American Brain Tumor Association

http://www.abta.org

Follow this link:
Personalized Medicine Extending to Supportive Needs of Brain Tumor Patients/Caregivers - PR Newswire (press release)

OXNARD, California and TEL AVIV, Israel, July 11, 2017 /PRNewswire/ CURE Pharmaceutical (OTCQB: CURR), (CURE), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (NASDAQ: Ltd. (Nasdaq: TRPX), (Therapix), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, announced today that they signed a memorandum of understanding (MOU) to enter into a research collaboration with Israels largest and leading private medical services center, Assuta Medical Centers, Ltd., (Assuta). The Companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids.

As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine, said Robert Davidson, CEO of CURE Pharmaceutical. Our new collaboration with Therapix and Assuta, two leading companies in Israel, a Country that is at the forefront of cannabinoid-based research in the world, is the perfect place to start the development of these products.

CURE is the ideal partner for us to enter this promising and cutting-edge personalized cannabinoid-based therapeutics; this deal has all the signs of a fruitful venture.

As agreed to in the MOU, the Companies intend to formalize the pooling of professional, scientific, financial resources and expertise, in order to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

Assuta is happy to enter into the MOU with CURE and Therapix, and I am confident that the parties cooperation will be a successful one, with many other projects to follow. This new collaboration is yet another step Assuta is taking in the innovation world, and one of many steps to be taken by Assuta in the field of biopharma.

About CURE Pharmaceutical

Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURE) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Companys mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life.

For more information about CURE Pharmaceutical, please visit its website at http://www.curepharmaceutical.com.

About Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Companys clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapixs unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapixs lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourettes Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist.

Please visit our website for more information at http://www.therapixbio.com.

About Assuta Medical Centers

Assuta Medical Centers (https://www.assuta.co.il/en/) is the largest private hospital network in Israel operating 8 hospitals and medical centers from north to south. Owned by Maccabi Healthcare, the second largest HMO in Israel, Assuta accounts for about 15% of the surgeries in Israel and takes care of the health of more than 1 million patients yearly. Assuta holds JCI quality accreditation with excellence and its service standards are ranked as top tier by the ministry of health.

Original press release:http://www.prnewswire.com/news-releases/cure-pharmaceuticaltherapix-biosciences-signs-mou-with-israels-assuta-medical-center-to-develop-first-in-class-therapeutic-products-in-fields-of-personalized-medicinecannabinoids-300486025.html

The most reliable, fact-based information on Therapix Biosciences found only on its Investor Dashboard.

Before this cannabis stock news is here, it's published to subscribers on 420 Investor.

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.

See original here:
CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel's Assuta Medical Center to Develop First-in ... - New Cannabis Ventures (blog)

Regenerative medicine is a revolutionary approach to treating many degenerative conditions and includes a variety of different techniques including stem cell therapy. This field joins nearly all disciplines of science and holds the realistic promise of repairing damaged tissue by harnessing the bodys ability to heal itself.

Adult stem cells are found in every part of the body and their primary role is to heal and maintain the tissue in which they reside. Stem cells are unspecialized cells capable of renewing themselves by cell division. In addition, they have the ability to differentiate into specialized cell types. Adult stem cells can be harvested from a patients own tissue, such as adipose (fat) tissue, muscle, teeth, skin or bone marrow.

One of the most plentiful sources of stem cells in the body is the fat tissue. In fact, approximately 500 times more stem cells can be obtained from fat than bone marrow. Stem cells derived from a patients own fat are referred to as adipose-derived stem cells. The mixed population of cells that can be obtained from fat is called a stromal vascular fraction (SVF). The SVF can easily be isolated from fat tissue in approximately 30-90 minutes in a clinic setting (under local anesthesia) using a mini-lipoaspirate technique. The SVF contains a mixture of cells including adipose-derived stem cells or ADSCs and growth factors and has been depleted of the adipocyte (fat cell) population.

ADSCs are multi-potential and can differentiate into a variety of different types of tissue including but not limited to bone, cartilage, muscle, ligament, tendon and fat. These cells have also been shown to express a variety of different growth factors and signaling molecules (cytokines), which recruit other stem cells to facilitate repair and healing of the affected tissue. ADSCs are very angiogenic in nature and can promote the growth of new blood vessels.

Based on research performed in our FDA registered facilities, stem cell quality and functionality can vary greatly depending on the methods utilized to obtain the cells. It is important to utilize a product that has undergone full characterization to include safety, identity, purity and potency. We have developed a method for harvesting and isolating stem cells from fat for therapeutic use. The use of a cell population that retains the ability to function in vivo will lead to more consistent patient results with long term success.

Adipose stem cells can be obtained from the patient easily, abundantly, and with minimal patient discomfort. Clinical applications for patients can be performed in an office setting safely, legally, and ethically using autologous ADSCs. Current applications include orthopedic conditions (tendon/ligament injuries, osteoarthritis, etc.), degenerative conditions (COPD, diabetes), neurological (MS, Parkinsons, spinal cord injuries, TBI, etc.) and auto-immune (RA, Crohns, colitis, lupus).

Stem cells possess enormous regenerative potential. The potential applications are virtually limitless. Patients can receive cutting edge treatments that are safe, compliant, and effective. Our team has successfully treated over 7000 patients with very few safety concerns reported. One day, stem cell treatments will be the gold standard of care for the treatment of most degenerative diseases. We are extremely encouraged by the positive patient results we are seeing from our physician-based treatments. Our hope is that stem cell therapy will provide relief and an improved quality of life for many patients. The future of medicine is here!

For additional information on our South Miami clinic, visit http://www.stemcellcoe.com.

Connect To Your Customers & Grow Your Business

Read more from the original source:
Regenerative Medicine: The Future of Medicine is Here - Miami's Community Newspapers

Mayo Clinic has confirmed that researchers from its regenerative medicine and genomics/individualized medicine programs will be among the first tenants of the initial Discovery Square medical office building in downtown Rochester.Last June, Mayo Business Development Chairman Jim Rogers told TCB that medical specialists from the clinics three transformational centers were among the likeliest early occupants of Discovery Squares first-phase building, which is seen as a key component in jump-starting Mayos ambitious Destination Medical Center effort.The trio of transformational centers include Center for Individualized Medicine, theCenter for Regenerative Medicine and theMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.Development plans for the 60,000-square-foot Discovery Square Phase I building were announced in April by Mortenson Construction, which will build and own the structure with Mayo signed on as lead tenant. The goal of Discovery Square is to place Mayo researchers into close collaboration with biotech and medtech companies seeking to commercialize their innovations, thus hopefully establishing Rochester as one of the countrys premier bio-business clusters while also getting new devices and therapies out to patients sooner.The clinic recently officially revealed that researchers concentrating in regenerative medicine and individualized medicine/genomicsalong with a new Mayo/industry collaborative biotech incubator spacewill indeed be among those who will be located within the 30,000 square feet leased by Mayo in the DS-1 building when It opens in 2019.Our research presence in Discovery Square will serve as a catalyst for ideas and projects that transform medicine and accelerate the discovery, translation and application of life-changing therapies and technologies so our patients receive exactly the care they need when its needed,Gregory Gores, M.D., Mayos executive dean of research, said in the announcement.Gores described the three aspects of Mayos presence in the DS-1 Building:Biotech incubator: Calling this space a true science incubator, Gores said its work will concentrate on developing innovative ways to apply technologies to be initially focused on ultrasound. Its designed to be expanded into other modalities and engineering technologies as needed. The space will enable interaction with industry partners to jointly enhance and develop new uses for biomedical devices.Advanced manufacturing of regenerative products: Mayo said this area will focus on creating products that can be used for therapeutic treatment, particularly products for regenerative therapies. It will be set up to enable the development and potentially the production of these new therapies.Genomics-based diagnostics center: The clinic will use this space to collaborate with outside groups on new medical tests that can better diagnose disease, specifically using genomics and other tools to focus on conditions that dont yet have clinical diagnostic tests and develop better tests for those that do.Mortenson says groundbreaking on the DS-1 project is planned for late this year with a target completion date in 2019. Designed by Minneapolis-based RSP Architects, the facility will be built on what is now a Mayo employee parking lot at the corner of 4th Street S.W. and 2nd Avenue S.W., in the 16-block Discovery Square sub-district of the larger Destination Medical Center planning zone.It features a unique, integrated design with flexible, open workspaces allowing Mayo researchers to adapt to ever-changing needs in the life science industry, while centralized common spaces within the building is designed to promote interaction among Mayo scientists and commercial collaborators also leasing space there.The 20-year DMC vision calls for an eventual office space build-out of 2 million square feet within the Discovery Square sub-district.

Original post:
Mayo Confirms First Tenants at Discovery Square Project - Twin Cities Business Magazine

Share this story with your network

BROOMFIELD, Colo.(BUSINESS WIRE)Regenexx, a Colorado-based stem-cell-treatment network and pioneer in the invention of interventional orthopedics, today announced that it successfully merged withHarbor View Medical, a leader in orthopedic stem cell therapy and part of the Regenexx network, which became effective in May 2017. As part of the transition, Jason Hellickson has assumed the CEO role. This merger positions Regenexx to further expand its National Network to better serve patients and our corporate partners.

Regenexx Corporate will be headquartered in Des Moines, IA, while Regenexxs Affiliate Program and Research and Development will be lead out of the companys Broomfield, CO location. Dr. Christopher Centeno, founder of orthopedic stem cell treatments and leader of interventional orthopedics in the United States and pioneer of the Regenexx patented procedures, will continue his role as Chief Medical Officer and remain in clinic operations in Broomfield, and continues the advancements of regenerative medicine through the largest research and data collection effort in orthopedic regenerative medicine.

As the most advanced non-surgical orthopedic care available in the United States, Im excited to continue our mission to producing the best possible patient outcomes through interventional orthopedics, said Jason Hellickson, CEO, Regenexx. In addition to individual personalized care, we will continue to provide both employers and their employees with cost savings results and successful interventions to orthopedic surgery.

Since joining the Regenexx Network in late 2014, Hellickson has reengineered clinic operations which increased capacity by more than 300 percent while offering a streamlined approach beneficial to both patients and clinic staff. He is the innovator and leader of theRegenexx Corporate Programthat enables large employers access to the Regenexx procedures. Since adding Regenexx procedures to their self-funded health and workers compensation plans, corporate partners have saved as much as 83 percent in their orthopedic surgical expenses, totaling in the many millions of dollars. In his new role, Hellickson will continue to architect the Regenexx national clinical operations to create more streamlined approaches to patient care and expand Regenexx clinics nationwide.

We look forward to continuing the build-out of Regenexx clinics, streamlining affiliate networks of more than 50 clinics nationwide, and adding additional clinics in major metropolitan areas including Chicago, Atlanta, Dallas, Philadelphia, and Charlotte under Jasons helm, said Christopher Centeno, MD. Were excited about the experience and enthusiasm that Jason brings to Regenexx.

Regenexx is the world leader in interventional orthopedics using orthobiologics and has been issued many patents for its evidence-based stem cell and blood platelet treatments used for back pain, joint pain, arthritis and acute orthopedic injuries. The benefits of interventional orthopedics are so revolutionary that seventy percent of orthopedic issues currently treated with surgery could instead be handled using regenerative methods. Mesenchymal stem cells are multipotent, adult stem cells that are therapeutic agents in the repair and regeneration of muscle, tissue, cartilage and bone. Regenexx procedures use a patients own bone marrow-derived stem cells, or blood platelets, through a blood draw, to customize needle-based, precisely-guided procedures to treat common orthopedic conditions. Its procedures have been proven to have the same or better outcomes compared to their surgical alternative.

For more information on the Regenexx Corporate Program call: 888-547-6667. For general information on Regenexx, please visitwww.Regenexxcorporate.com. For a map of current Regenexx clinics and providers clickhere.

About Regenexx and the Regenexx Physician NetworkThe Regenexx Procedures are the nations most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patients own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.

For more information on Regenexx, please visit:http://www.regenexx.com

Here is the original post:
Regenexx Announces Successful Merger with Harbor View Medical - OrthoSpineNews

Conference Series Ltdinvites all the members of Biological Sciences family, from all over the world to join and share research at the10th World Congress on Stem Cell and Biobankingduring 23th& 24thOctober, 2017 at Osaka, Japan, which includes prompt keynote presentations, plenary talks, oral talks, poster presentations and exhibitions.

Theme: Accelerating the Innovative Research &Technology in Stem Cell & Biobanking

Stem Cell Convention 2017aims in proclaim knowledge and share new ideas amongest the professionals, industrialists and students from research area of Stem Cells and Biobanking to share their research experiences and indulge in interactive discussions at the event. This scientific gathering guarantees that offering the thoughts and ideas will enable and secure you the theme Accelerating the Innovative Research &Technology in Stem Cell & Biobanking. Biobanking is the latest trending technology in many fields. The current era fully rolled out with many new Stem cells and Biobanking technologies. In such case more research centres and Hospitals were newly introduced within market which obviously shows the market growth of stem cells and Biobanking techniques. While analyzing the revenue growth of stem cells research, it highly developed from $150 billion USD to $250 billion USD since from 2010-2015. And the annual growth percentage increases from 20-55 percentages.

Track-1

Stem Cells Biology

Stem cellsare undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells:embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells andprogenitor cellsact as a repair system for the body, replenishingadult tissues. In a developing embryo, stem cells can differentiate into all the specialized cellsectoderm, endoderm and mesoderm (see induced pluripotent stem cells)but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.Umbilical cord cells are also included in this Stem Cell Research.

Related Stem Cell Convention | Stem Cell Conferences | Biobanking Congress | Stem Cell Banking|Cord Blood Stem Cell Research|

7th Annual Conference on Stem Cell and Regenerative Medicine ,Aug 4-5, 2016, Manchester, UK; 2nd International Conference on Antibodies,July 14-15, 2016 ,Philadelphia, USA; 2nd International Conference on Innate Immunity,July 21-22, 2016 ,Berlin, Germany; 2nd International Congress on Neuroimmunology ,March 31-April 02, 2016, Atlanta, USA; International Conference on Cancer Immunology ,July 28-30, 2016 ,Melbourne, Australia.

Stem cells technologyis a rapidly developing field that combines the efforts of cell biologists,geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases. Stem cells are defined astotipotent progenitor cellscapable of self-renewal and multilineage differentiation. Stem Cell s technologysurvive well and show stable division in culture, making them ideal targets for in vitro manipulation. Although early research has focused on hematopoietic stem cells, stem cells have also been recognised in other sites. Research into solid tissue stem cells has not made the same progress as that on hematopoietic stem cells. This is due to the difficulty of reproducing the necessary and precise three dimensional arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. However, the ability of tissue stem cells to integrate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues makes them ideal for cell replacement therapy. Some of the methods of Stem Cells technology include Cord Stem Cell Transplantation, Allogeneic stem cell transplantation.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

8th World Congress on Stem Cell Research ,March 20-22, 2017 ,Orlando, USA;International Conference on Cancer Immunology ,July 28-30, 2016 ,Melbourne, Australia; 5th International Conference on Immunology ,October 24-26, 2016 ,Chicago, USA; Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, Mar 610 2016, Whistler, Canada; Systems Immunology: From Molecular Networks to Human Biology, Jan 1014 2016, Big Sky, USA.

Track-3

Stem Cells Therapy Research

Stem cells therapyis the use of stem cells to treat or prevent a disease or condition.Bone marrow transplantis the most widely used stem-cells therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources forstem cells, and to apply stem-cells treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions.Cord blood stem cells therapy is highly recommended at the time of delivery to save the umbilical cord of the child to resolve any future health conditions. Umbilical cord stem cells research has more scope to resolve the issues caused due to DNA changes.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thInternationalConference on Plant Genomics,July 14-15, 2016 ,Brisbane, Australia; 8thWorld Congress on Stem Cell Research,March 20-22, 2017 ,Orlando, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016, Manchester, UK; 2ndInternationalConference on Tissue preservation and Biobanking,September 12-13, 2016 ,Philadelphia, USA;World Congress on Human Genetics,October 31- November 02, 2016 ,Valencia, Spain.

Track-4

Epigenetics

Epigeneticsis the study of potentially heritable changes in gene expression (active versus inactive genes) that does not involve changes to the underlyingDNA sequence a change in phenotype without a change in genotype which in turn affects how cells read the genes. Epigenetic change is a regular and natural occurrence but can also be influenced by several factors including age, the environment/lifestyle, and disease state. Epigenetic modifications can manifest as commonly as the manner in which cells terminally differentiate to end up as skin cells, liver cells, brain cells, etc. Or, epigenetic change can have more damaging effects that can result in diseases like cancer. At least three systems includingDNA methylation, histone modification and non-coding RNA (ncRNA)-associated gene silencing are currently considered to initiate and sustain epigenetic change. New and ongoing research is continuously uncovering the role of epigenetics in a variety ofhuman disordersand fatal diseases.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Next Generation Sequencing,July 21-22, 2016 ,Berlin, Germany; 5thInternationalConference on Computational Systems Biology,August 22-23, 2016 ,Philadelphia, USA; 7thInternationalConference on Bioinformatics,October 27-28, 2016 ,Chicago, USA; InternationalConference on Synthetic Biology,September 28-30, 2015 ,Houston, USA; 4thInternationalConference on Integrative Biology,July 18-20, 2016 ,Berlin, Germany.

Track-5

Stem cells apoptosis and signal transduction

Self-renewal and proliferation ofstem cellspopulation is controlled, in part, by induction of apoptosis. The number of stem cells is therefore a balance between those lost to differentiation / apoptosis and those gained through proliferation.Apoptosisof stem cells is believed to be a dynamic process which changes in response to environmental conditions. For example, the release of stem cells factor inhibits apoptosis following spinal cord injury, presumably in an attempt to promotetissue repair. Dysregulation of apoptosis instem cellsis believed to underlie somecancer pathologies, where apoptotic resistance results in uncontrolled growth (i.e. glioblastoma). Controlling apoptosis is also an important focus for studies ofstem cells transplantation, where inhibition may increase the survival of grafted cells during replacement therapy. Harnessing the full therapeutic potential of stem cells will require full elucidation of the signal transduction cascades for proliferation, differentiation, and apoptosis.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

7thInternationalConference on Bioinformatics,October 27-28, 2016 ,Chicago, USA; InternationalConference on Synthetic Biology,September 28-30, 2015 ,Houston, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016, Manchester, UK; 4thInternationalConference on Integrative Biology,July 18-20, 2016 ,Berlin, Germany; 1stInternationalConference on Pharmaceutical Bioinformatics,Jan 2426 2016, Pattaya, Thailand.

Trcak-6

Regenerative medicine

Regenerative medicineis the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Restorative Medicine,October 24-26, 2016 ,Chicago, USA; 3rdWorld Congress onHepatitis and Liver Diseases,October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular Biology,October 13-15, 2016 ,Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking, September12-13, 2016 ,Philadelphia USA; 26thEuropean Congress ofClinical Microbiology, April 912 2016, Istanbul, Turkey;Conference onCell Growth and Regeneration, Jan 1014 2016, Breckenridge, USA.

Track-7

Bio-banks

Biobanksplay a crucial role in biomedical research. The wide array ofbio specimens(including blood, saliva, plasma, and purified DNA) maintained inbiobankscan be described as libraries of the human organism. They are carefully characterized to determine the general and unique features of the continuous cell line and the absence or presence of contaminants, therefore establishing a fundamental understanding about the raw material from which the biological product is being derived and maintained.Biobankscatalog specimens using genetic and other traits, such as age, gender, blood type, and ethnicity. Some samples are also categorized according to environmental factors, such as whether the donor had been exposed to radiation, asbestos, or some other substance that can affecthuman genes.In Biobank Category the most popular biobank projects includes cord blood banking, banking stem cells, baby cord blood banking.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

8thWorld Congress on Stem Cell Research,March 20-22, 2017 ,Orlando, USA; 5thInternationalConference onCell and Gene Therapy,May 19-21, 2016 ,San Antonio, USA; 7thAnnual Conference on Stem Cell and Regenerative Medicine,Aug 4-5, 2016 ,Manchester, UK; InternationalConference on Restorative Medicine,October 24-26, 2016 ,Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE.

Track-8

Stem cells biomarkers

Bio markeris a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A bio marker may be used to see how well the body responds to a treatment for a disease or condition.

In cancer research and medicine, bio markers are used in three primary ways:

To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)

To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)

To predict how well a patient will respond to treatment (Predictive).

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Genetic Counseling and Genomic Medicine,August 11-12, 2016 ,Birmingham, UK;World Congress on Human Genetics,October 31- November 02, 2016 ,Valencia, Spain; InternationalConference on Molecular Biology,October 13-15, 2016 ,Dubai, UAE; 3rdInternationalConference on Genomics & Pharmacogenomics,September 21-23, 2015 ,San Antonio, USA; EuropeanConference on Genomics and Personalized Medicine ,April 25-27, 2016 ,Valencia, Spain.

Track-9

Cells & Organ Regeneration

Regenerationmeans the regrowth of a damaged or missing organ part from the remaining tissue. As adults, humans can regenerate some organs, such as the liver. If part of the liver is lost by disease or injury, the liver grows back to its original size, though not its original shape. And our skin is constantly being renewed and repaired. Unfortunately many other human tissues dont regenerate, and a goal inregenerative medicineis to find ways to kick-start tissue regeneration in the body, or to engineerreplacement tissues.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 ,San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,Oct 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-10

Fertility biobanks

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into howcanceraffects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos afterin vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

Related Stem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 ,San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology ,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-11

Biobank Ethics

Ethical issues are commonly present in many aspects ofBiobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to abiobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in Biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research usinghuman tissuematerial and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.

American Society forBioethicsand Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxford shire, UK, CFP: Global Forum on Bioethics in Research Foundation Merieux, France, Hands On Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, TheBiomarker ConferenceOrlando, Florida USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases,May 16-18, 2016 San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Track-12

Market Analysis in Biobanking

The globalbiopreservationmarket is expected to reach USD 3,731.03 Million by 2020 from USD 2,150.48 Million in 2015, growing at a CAGR of 11.65% between 2015 and 2020. Biopreservation is used to ensure the stability, quality and purity ofbiospecimens. With a CAGR of 23.7%, global market value for cryopreservation equipment used instem cellsindustry is anticipated to worth US$2.2 billion by 2015. On a global scale, North America accounts for nearly 35% of the market and will likely witness a higher growth rate in the upcoming years, in comparison with Asia-Pacific. While US accounts for the highest share of the global market value on a country basis, India and China surpasses the US in terms of growth rate anticipated in the near future. As per our analysis, freezers represent more than half of thecryopreservationequipment market value while Cyropreservative reagents stand for a share of close to 20%. The global biopreservation market is poised for rapid growth between 2015 and 2020. The drivers include increasing healthcare expenditure, growing demand for preserving new-borns stem cells, increasing R&D spending on research, and increasing adoption ofregenerative medicine.

RelatedStem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

InternationalConference on Case Reports,March 31-April 02, 2016 ,Valencia, Spain; 2nd International Meeting onClinical Case Reports,April 18-20, 2016 ,Dubai, UAE; 3rd Experts Meeting onMedical Case Reports,May 09-11, 2016 ,New Orleans, Louisiana, USA; 12thEuro BiotechnologyCongress,November 7-9, 2016 ,Alicante, Spain; 2nd InternationalConference onTissue preservation and Biobanking,September 12-13, 2016 ,Philadelphia, USA.

Track-13

Next Generation Biobanking

Biorepositoriesprovide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standardbiobanking practicesand characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at theLung Tissue ResearchConsortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients.

Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, HandsOn Biobanks 2016 conference Vienna, Austria, American Society forBioethicsand Humanities Houston, USA, Craniofacial Morphogenesis &Tissue RegenerationVentura, CA, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell &Gene TherapyWorld Washington D.C., USA, Notch Signaling in Development, Regeneration & Disease Gordon Research Conference Lewiston, ME, USA.

The biobanking market is poised for explosive growth if it can overcome the challenges of an adolescent industry. According to an August 2012 Infiniti Research report titled Global Biobanking Market 2011-2015, the biobanking market will increase 30 per cent from 2011 to 2015 to nearly $183 billion. Growth is being driven by an increase in populationgeneticsstudies, personalized medicine, and the use of genetic information in food safety, forensics, and disease surveillance.

Related Stem Cell Convention|Stem Cell Conferences|Biobanking Congress|Stem Cell Banking|Cord Blood Stem Cell Research|

4thCongress on Bacteriology and Infectious Diseases, May 16-18, 2016 San Antonio, USA; 2ndWorld Congress on Applied Microbiology,October 31-November 02, 2016 ,Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic Microbiology,October 3-5, 2016 ,Vancouver, Canada; InternationalConference on Water Microbiology ,July 18-20, 2016 ,Chicago, USA; 5thInternationalConference on Clinical Microbiology,October 24-26, 2016 ,Rome, Italy.

Follow this link:
Stem Cell and Biobanking - Stem Cell Conferences

Lisa Rathke, AP Images

Media portrayals of campus controversies, as when students shouted down Charles Murray at Middlebury College earlier this year, contribute to negative views of colleges among Republicans.

A majority of Republicans and right-leaning independents think higher education has a negative effect on the country, according to a new study released by the Pew Research Center on Monday. The same study has found a consistent increase in distrust of colleges and universities since 2010, when negative perceptions among Republicans was measured at 32 percent. That number now stands at 58 percent.

The divides between folks on the left and folks on the right are getting more serious.

By comparison, 72 percent of Democrats or left-leaning Independents in the study said colleges and universities have a positive impact on the United States.

In an increasingly polarized culture, the drastic shift is the latest piece of evidence that institutions of higher education along with labor unions, banks, churches, and the news media have been plunged headfirst into a hyperpartisan war.

That war started a long time ago, though its intensified lately. "The divides between folks on the left and folks on the right are getting more serious," said Neil L. Gross, a professor of sociology at Colby College and author of the book, Why Are Professors Liberal and Why Do Conservatives Care? "I dont think theres any evidence that its going to subside anytime soon."

For years, higher education has been viewed favorably by liberals and less so by conservatives, Mr. Gross said, but political controversies in the past year have drawn attention and increased the negative perception. Protests and incidents of speakers being actively opposed or threatened by students are widely reported, he said, and are often one of the few ways in which the general population encounters college campuses.

"Its not surprising how people hold onto publicly available narratives on college campuses," he said. "I think its understandable, though regrettable."

David Hopkins, an associate professor at Boston College and co-author of Asymmetric Politics: Ideological Republicans and Group Interest Democrats, said the negative view of colleges and universities is an expectable manifestation of this increase in coverage of college campuses. For instance, the website Campus Reform is a steady purveyor of perceived liberal bias on college campuses, and such controversies are often featured on the Fox News program Tucker Carlson Tonight.

"This has become a major subject of conservative coverage of contemporary politics and contemporary campus life," Mr. Hopkins said. "Its no surprise an echo of that coverage would start to show up in public opinion on the right."

That reporting, Mr. Hopkins said, has only exacerbated an existing distrust of colleges and universities among conservative thinkers.

The conservative critique of the social sciences in the mid- and late-1900s, he said, has grown to include the hard sciences in the last 20 years, largely among subjects like stem-cell research, climate change, and evolution.

A change in the demographics of both parties has also influenced the mistrust of colleges, he said. Whereas 50 years ago, the best predictor of conservative alignment was a high level of education, Mr. Hopkins said, "the popular base of the Republican party is less and less white-collar professionals and is more and more white working-class non-college-educated voters." Whether or not someone had a college degree was considered by many observers to be the most compelling predictor of whether they voted Republican or Democrat in the last presidential election.

This change has given rise to a perception by conservatives of liberal elitism an impression that can frame institutions of higher education as inherently partisan, according to Sean J. Westwood, an assistant professor of social science at Dartmouth College and a co-author of the recent study "Fear and Loathing Across Party Lines: New Evidence on Group Polarization."

Colleges are simply seen as a production facility for Democratic beliefs and Democratic ideology.

"There is a perception that Democratic elites are well-educated and Republicans are more of the common man," Mr. Westwood said. "Colleges are simply seen as a production facility for Democratic beliefs and Democratic ideology."

In the Pew Research Centers study, distrust of colleges was strongest in the highest income bracket and the oldest age group, with approval levels of just 31 percent among respondents whose family income exceeds $75,000 a year and 27 percent among those older than 65.

Favor for higher education was highest among Republicans who are younger than 29 (52 percent) and those who have not completed a college degree (37 percent).

Outside of party beliefs, Mr. Gross said, higher education is not a big part of an average persons life. If thats true, he said, then many of the answers given on such polls may not come from personal experience. "Theyre very likely just filling in the blanks from their partisan knowledge and opinions," Mr. Gross said. "Part of what it means to be a conservative and a Republican is to voice opposition to liberal tendencies on college campuses."

"People are essentially taking cues from party leaders and conservative media," he said, "about opinions they are supposed to have."

Read this article:
Most Republicans Think Colleges Are Bad for the Country. Why ... - The Chronicle of Higher Education

Acupuncture

Acupuncture is a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. It is one of the most effective practices used in traditional Chinese medicine. Acupuncture stimulates nerve fibers to transmit signals to the spinal cord and brain, activating the bodys central nervous system. The spinal cord and brain then release hormones responsible for making us feel less pain while improving overall health. Acupuncture may also: increase blood circulation and body temperature, affect white blood cell activity (responsible for our immune function), reduce cholesterol and triglyceride levels, and regulate blood sugar levels.

Aquatherapy

Aquatic Physical Therapy is the practice of physical therapy in a specifically designed water pool with a therapist. The unique properties of the aquatic environment enhance interventions for patients with neurological or musculoskeletal conditions. Aquatic therapy includes a wide range of techniques allowing patients to improve their balance, muscle strength and body mechanics. Aquatic therapy works to enhance the rehabilitation process and support effectiveness of stem cell treatment.

Epidural Stimulation

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the medical use of oxygen at a level higher than atmospheric pressure. The equipment required consists of pressure chamber, which may be of rigid or flexible construction, and a means of delivering 100% oxygen into the respiratory system. Published research shows that HBOT increases the lifespan of stem cells after injection and provides an oxygen-rich atmosphere for the body to function at optimum levels.

Nerve Growth Factor (NGF)

Nerve growth factor (NGF) is a member of the neurotrophic factor (neurotrophin, NTFS) family, which can prevent the death of nerve cells and has many features of typical neurotransmitter molecules. NGF plays an important role in the development and growth of nerve cells. NGF is synthesized and secreted by tissues (corneal epithelial, endothelial, and corneal stromal cells), and it can be up-taken by sympathetic or sensory nerve endings and then transported to be stored in neuronal cell bodies where it can promote the growth and differentiation of nerve cells.NGF can exert neurotrophic effects on injured nerves and promote neurogenesis (the process of generating neurons from stem cells) that is closely related to the development and functional maintenance and repair of the central nervous system. It is also capable of promoting the regeneration of injured neurons in the peripheral nervous system, improving the pathology of neurons and protecting the nerves against hypoxia (lack of oxygen)/ischemia (lack of blood supply).

Nutrition Therapy

Occupational Therapy

Occupational therapy interventions focus on adapting the environment, modifying the task and teaching the skill, in order to increase participation in and performance of daily activities, particularly those that are meaningful to the patient with physical, mental, or cognitive disorders. Our Occupational Therapists also focus much of their work on identifying and eliminating environmental barriers to independence and participation in daily activities, similar to everyday life.

Physiotherapy

Physical therapy or physiotherapy (often abbreviated to PT) is a physical medicine and rehabilitation specialty that, by using mechanical force and movements, remediates impairments and promotes mobility, function, and quality of life through examination, diagnosis, prognosis, and physical intervention. We combine our PT with stem cells for maximum physical rehabilitation improvements.

Transcranial Magnetic Stimulation

Research has shown that TMS can effectively treat symptoms of depression, anxiety, neurological pain, stroke, spinal cord injuries, autism and more. This procedure is very simple and noninvasive. During the procedure, a magnetic field generator or coil is placed near the head of the person receiving the treatment. The coil produces small electrical currents in the region of the brain just under the coil via electromagnetic induction. This electrical field causes a change in the transmembrane current of the neuron which leads to depolarization or hyperpolarization of the neuron and the firing of an action potential.

Read the rest here:
Stem Cell Treatment for Traumatic Brain Injury - Beike ...

Researchers at the University of Colorado Anschutz Medical Campus discovered that a process protecting the body from autoimmune disease appears to prevent it from creating antibodies that can neutralize the HIV-1 virus, a finding that could possibly help lead to a vaccine that stimulates production of these antibodies.

Lead researcher Raul M. Torres and his team sought to better understand how the bodys own immune system might be getting in the way of neutralizing the HIV-1 virus.

They knew that some patients infected with HIV-1 developed what are known as broadly neutralizing antibodies, or bnAbs, that can protect against a wide variety of HIV-1 strains by recognizing a protein on the surface of the virus called Env. But the patients only develop these antibodies after many years of infection. Because of shared features found in a number of HIV-1 bnAbs, researchers suspected the inability or delayed ability to make these type of protective antibodies against HIV was due to the immune system suppressing production of the antibodies to prevent the body from creating self-reactive antibodies that could cause autoimmune diseases like systemic lupus erythematosus.

At the same time, patients with lupus showed slower rates of HIV-1 infection. Scientists believe thats because these autoimmune patients produce self-reactive antibodies that recognize and neutralize HIV-1. The process by which the body prevents the creation of antibodies that can cause autoimmune disease is known as immunological tolerance. Torres wanted to break through that tolerance and stimulate the production of antibodies that could neutralize HIV-1. We wanted to see if people could make a protective response to HIV-1 without the normal restraint imposed by the immune system to prevent autoimmunity, Torres said.

The researchers first tested mice with genetic defects that caused lupus-like symptoms. They found that many of them produced antibodies that could neutralize HIV-1 after being injected with alum, a chemical that promotes antibody secretion and is often used in vaccinations. Next, they treated normal mice with a drug that impairs immunological tolerance and found that they began producing antibodies capable of neutralizing HIV-1. The production of these antibodies was increased by alum injections. And if the mice were also injected with the HIV-1 protein Env, they produced potent broadly neutralizing antibodies capable of neutralizing a range of HIV-1 strains.

In every case, the production of these HIV-neutralizing antibodies correlated with the levels of a self-reactive antibody that recognizes a chromosomal protein called Histone H2A. The researchers confirmed these antibodies could neutralize HIV-1. We think this may reflect an example of molecular mimicry where the virus has evolved to mimic or look like a self protein, Torres said.

Torres suggested that the difficulty in developing a vaccine against HIV-1 may be because of the ability of the virus to camouflage itself as a normal part of the body. But breaching peripheral immunological tolerance permits the production of cross-reactive antibodies able to neutralize HIV-1, Torres said.

Since the research was done on animals, scientists must still determine its relevance for HIV-1 immunity in humans. The primary consideration will be determining whether immunological tolerance can be temporarily relaxed without leading to detrimental autoimmune manifestations and as a means to possibly elicit HIV-1 bnAbs with vaccination, he said. The study is published in The Journal of Experimental Medicine.

Follow @htlifeandstyle for more

Read the original here:
Breakthrough: Switching immune system off can turn HIV protection on - Hindustan Times

Credit: CC0 Public Domain

Immune system function varies significantly between individuals, and up to now there has been no effective means of measuring and describing these differences. Now, researchers at Karolinska Institutet have shown that white blood cell composition is unique in individuals, and that the composition of these cells may predict immune system response to various forms of stimulation. The study, which is published in PNAS, paves the way for more individualised treatment of diseases involving the immune system, e.g. autoimmune disorders, allergies and various forms of cancer.

The human immune system comprises a complex network of different white blood cells, which coordinate their efforts in order to combat different external and internal threats. This network varies widely between different individuals, but the differences have been difficult to measure and understand.

Together with colleagues at the Massachusetts Institute of Technology (MIT) and Stanford University in the USA, researchers at Karolinska Institutet and the Science for Life Laboratory (SciLifeLab) have developed a tool for measuring the unique composition of white blood cells in individuals. Researchers have also found that the test may predict how individuals will respond to a given treatment, e.g. individual response to an influenza vaccine.

Measuring the individual's "immunotypes"

"By measuring all populations of white blood cells in the blood at the same time, we can describe the composition of an individual's immune system and show that this is unique for the individual. We call this measure, the individual's "immunotype". We have also found that this immunotype makes the complex immune system more understandable and predictable," says Petter Brodin, physician and researcher at SciLifeLab and the Department of Medicine, Solna, at Karolinska Institutet.

A human immunotype is not constant, but varies over time in response to external factors. In previous studies, Petter Brodin and his research colleagues have shown that in humans individual differences in immune defence can be attributed primarily to the many different environmental factors unique to each individual, e.g. diet, infections, vaccines and microflora.

Blood samples from 1,500 individuals

In the study in question, the researchers analysed blood samples from approximately 1,500 healthy individuals and tested in vitro how their white blood cells respond to different stimuli. They have also vaccinated individuals against influenza and studied which antibody protection the individuals developed thereafter. It transpired that all different types of stimulation could be predicted based on the individual's immunotype, which was surprising according to Petter Brodin.

"Our technique can be scaled up, and my hope is that eventually it will be used clinically to predict those individuals who may benefit from a particular immunological treatment or a certain vaccine. The technique may also contribute to more individualised drugs to treat autoimmune disease and allergies, as well as immunotherapy to treat cancer, which can be adapted based on the individual's immune response," says Petter Brodin.

Explore further: Differences in individuals' immune responses linked to flu vaccine effectiveness

More information: Kevin J. Kaczorowski et al. Continuous immunotypes describe human immune variation and predict diverse responses, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1705065114

Read more:
New tool demonstrates differences in human immune systems - Medical Xpress

Q. I seem to be getting sick a lot lately, and Im worried that my immune system isnt working right. Could that be a reason?

A diminished immune system could be the cause of your problems. Go to your doctor for a checkup and diagnosis.

The immune system is a network of cells, tissues, and organs that work together to defend the body against attacks by organisms such as bacteria, parasites, and fungi that can cause infections.

The cells that are part of this defense system are white blood cells, or leukocytes. Foreign substances that invade the body are called antigens.

No two individuals have the same immune system. Some people seem to be dressed in a suit of armor against infections while others get floored whenever there are bugs about.

When it comes to germs, getting older has advantages and disadvantages.

As we age, our immune systems develop defenses against antigens. We acquire antibodies to the germs weve defeated in the past. Because of this phenomenon, adults tend to get fewer colds than children.

Now for some of the bad news that comes with advancing age:

The thymus, which is located behind the breastbone, is one of the organs of the immune system. The thymus is where immune cells - white blood cells - called T lymphocytes (T cells) mature. The thymus begins to shrink when we are young adults. By middle age it is only about 15 percent of its maximum size.

Some T cells kill antigens directly. Others help coordinate other parts of the immune system. Although the number of T cells does not decrease with aging, T-cell function decreases. This causes parts of the immune system to weaken and increases the risk for becoming ill.

Macrophages, which are white blood cells that ingest antigens, dont work as quickly as they used to in younger years. This slowdown may be one reason that cancer is more common among older people.

There are fewer white blood cells capable of responding to new antigens. Thus, when older people encounter a new antigen, the body is less able to remember and defend against it.

The amount of antibodies produced in response to an antigen is less in older people, and the antibodies are less able to attach to the antigen. These changes may partly explain why pneumonia, influenza, infectious endocarditis, and tetanus are more common among older people and cause death more often. These changes may also partly explain why vaccines are less effective in older people.

Later in life, the immune system also seems to become less tolerant of the body's own cells. Sometimes an autoimmune disorder develops; normal tissue is mistaken for non-self tissue, and immune cells attack certain organs or tissues. Among the autoimmune disorders are lupus, rheumatoid arthritis, scleroderma and ankylosing spondylitis.

Diabetes, which is also more common with increasing age, can also lead to decreased immunity.

There are immunizations that are important as we get older. Adult tetanus immunizations should be given every 10 years; a booster may be given sooner if there is a dirty wound.

Your healthcare provider may recommend other immunizations, including Pneumovax (to prevent pneumonia or its complications), flu vaccine, hepatitis immunization, or others. These optional immunizations are not necessary for all older people, but are appropriate for some.

Follow this link:
Regular checkups can combat immune-system slowdown - CapeGazette.com

Boost your immune system and take a preventative approach to your wellbeing this winter.

Photos: Instagram @emrata, @selenagomez

As the number of new flu viruses set to hit our shores this year increases, so too do the studies that show theres a multitude of ways to protect your immune system this winter. Got the chicken soup, antiseptic hand gel and multivitamins? Add the following into your daily routine for improved fortification against colds and flu.

Book in for a 20-minute weekly massage and you could lower your cortisol levels a stress hormone that negatively impacts the immune system by up to 53 per cent, according to researchers at the Touch Research Institute at the University of Miami School of Medicine in the US. Regular moderate pressure massage has also been shown to increase the production of dopamine and serotonin, flooding your body with the kind of happy hormones that no amount of bad weather can affect. Live in Sydney, Melbourne or Brisbane? Try new mobile massage on demand service, Blys. Think of it as the Uber of qualified therapists.

Scientists at Finlands University of Turku found that a slice per day of probiotic rich cheese, such as Gouda, can boost immunity, as can a daily pot of yoghurt, according to researchers at the University of Vienna, Austria.

Having sex frequently can boost your immune system, according to researchers at Wilkes University in the US, who found that university students who engaged in sexual activity once or twice per week had higher levels of immunoglobulin A (an antibody that helps fights infections) in their saliva. Those who had no sex or very frequent sex (three or more times per week) had lower levels.

Human connection has long been linked to peak physical health, but researchers at Carnegie Mellon University in the US have gone one further and discovered that the larger your social group, the better your chance of escaping winter untouched by influenza. They gave 83 college students the flu vaccine and found that those who enjoyed the company of a larger circle of friends (real ones, not Facebook mates), produced more flu-fighting antibodies than those who preferred more intimate groups. To get in on the action, consider joining or starting a book club or other hobby group based on your interests.

High levels of vitamin D and increased immune health go hand-in-hand, but researchers at the University of Sydney have discovered that out of the 24,000 people they tested, 58 per cent were deficient in the vitamin, putting them at risk of a host of illnesses and diseases. To keep your body fighting fit, aim to get 20 minutes of sunshine (the most potent source of vitamin D) in the winter months, preferably in the morning or late afternoon, outside peak UV hours.

Make the most of those glorious goose-down pillows and winter-weight quilts and commit to sleeping at least seven hours a night, researchers at the University of California San Francisco in the US advise. They found that those who sleep six hours or less per night are four times more likely to catch a cold when exposed to the virus than those who sleep seven or more.

Regular moderate activity really is the first line of defence against colds and flu. US researchers who studied more than 1000 people found that those who did five or more days of exercise a week experienced 43 per cent fewer days with upper respiratory tract infections than those who exercised one day or less. And when they did get a cold, the frequent exercisers suffered milder symptoms than the less frequent.

Cold and flu germs are easily transmitted via hand-to-hand contact, so try to get into the habit of washing your hands regularly with soap throughout the day. Need encouragement? Researchers from San Diegos Naval Health Research Centre in the US saw a 45 per cent decrease in respiratory illness among its 45,000 recruits who had been instructed to wash their hands at least five times a day.

Meeting friends for coffee? Studies show swapping your usual latte for a soothing cup of chamomile increases antibacterial activity within your body, helping to boost immunity and fight infections associated with colds. If youre not a fan of the taste, inhaling steam infused with chamomile extract can be just as helpful in warding off a cold.

A study from the University of Kentucky in the US found that as people become more optimistic, their bodies better resist invasion by viruses and bacteria.

Original post:
How to stay well when everyone around you is coughing up phlegm - Body and Soul

14 June, 2017

The ISSCR is pleased to announce Hans Clevers, Hubrecht Institute, the Netherlands, as the incoming president of the ISSCR and its board of directors. Clevers assumes the post immediately following the 15th ISSCR Annual Meeting in Boston, 14-17 June, 2017.

08 May, 2017

The ISSCR wrote to members of the Texas House of Representatives, U.S., to oppose House Bill 661, House Bill 810, and House Bill 3236, which would allow investigational agents to be sold to patients without first providing rigorous evidence of safety and efficacy. The ISSCR believes the legislation would put patients at serious risk of harm from unproven treatments.

25 April, 2017

Progress in stem cell research and its translation to the clinic will be the focus of the International Society for Stem Cell Research (ISSCR) annual meeting 14-17 June at the Boston Convention and Exhibition Center, Boston, Mass. More than 4,000 stem cell scientists, bioethicists, clinicians, and industry professionals from over 50 countries will share and discuss the latest discoveries and technologies within the field, and how they are advancing regenerative medicine.

17 March, 2017

The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.

Link:
International Society for Stem Cell Research

By Reuters By Reuters July 8

Stem cell tourism in which patients travel to developing countries for unproven and potentially risky therapies should be more tightly regulated, according to a group of international health experts.

With hundreds of medical centers around the world claiming to be able to repair tissue damaged by conditions such as multiple sclerosis and Parkinsons disease, tackling unscrupulous advertising of such procedures is crucial.

These therapies are advertised directly to patients with the promise of a cure, but there is often little or no evidence to show they will help or that they will not cause harm, the 15 experts wrote in the journal Science Translational Medicine.

Some types of stem cell transplant mainly using blood and skin stem cells have been approved by regulators after full clinical trials found they could treat certain types of cancer and grow skin grafts for burn patients.

But many other potential therapies are only in the earliest stages of development and have not been approved by regulators.

Stem cell therapies hold a lot of promise, but we need rigorous clinical trials and regulatory processes to determine whether a proposed treatment is safe, effective and better than existing treatments, said one of the 15, Sarah Chan of Britains University of Edinburgh.

The experts called for global action, led by the World Health Organization, to introduce controls on advertising and to agree on international standards for the manufacture and testing of cell- and tissue-based therapies.

The globalization of health markets and the specific tensions surrounding stem cell research and its applications have made this a difficult challenge, they wrote. However, the stakes are too high not to take a united stance.

Read the rest here:
'Stem-cell tourism' needs tighter controls, say medical experts - Washington Post